Cited by 154Mitochondrial Function and PathologyMetabolism, Diabetes, and CancerAdipose Tissue and Metabolism

The Role of Mitochondria in the Pathophysiology of Skeletal Muscle Insulin Resistance

Open access
Pagel-Langenickel, Ines, Bao, Jianjun, Pang, Liyan, Sack, Michael N.·2010·Endocrine Reviews

Abstract

Multiple organs contribute to the development of peripheral insulin resistance, with the major contributors being skeletal muscle, liver, and adipose tissue. Because insulin resistance usually precedes the development of type 2 diabetes mellitus (T2DM) by many years, understanding the pathophysiology of insulin resistance should enable development of therapeutic strategies to prevent disease progression. Some subjects with mitochondrial genomic variants/defects and a subset of lean individuals with hereditary predisposition to T2DM exhibit skeletal muscle mitochondrial dysfunction early in the course of insulin resistance. In contrast, in the majority of subjects with T2DM the plurality of evidence implicates skeletal muscle mitochondrial dysfunction as a consequence of perturbations associated with T2DM, and these mitochondrial deficits then contribute to subsequent disease progression. We review the affirmative and contrarian data regarding skeletal muscle mitochondrial biology in the pathogenesis of insulin resistance and explore potential therapeutic options to intrinsically modulate mitochondria as a strategy to combat insulin resistance. Furthermore, an overview of restricted molecular manipulations of skeletal muscle metabolic and mitochondrial biology offers insight into the mitochondrial role in metabolic substrate partitioning and in promoting innate adaptive and maladaptive responses that collectively regulate peripheral insulin sensitivity. We conclude that skeletal muscle mitochondrial dysfunction is not generally a major initiator of the pathophysiology of insulin resistance, although its dysfunction is integral to this pathophysiology and it remains an intriguing target to reverse/delay the progressive perturbations synonymous with T2DM.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/er.2009-0003

Cites

331 of 331 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Lower fatty acid oxidation plus higher cytosolic free fatty acids ultimately produce conditions including type 2 diabetes, muscle dysfunction, and insulin resistance.

    “Consequently, an observed decrease in fatty acid oxidation and an increase in cytosolic levels of free fatty acids ultimately lead to pathologies such as type 2 diabetes mellitus (T2DM), muscle dysfunction and insulin resistance125.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 333 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Pagel-Langenickel, I., Bao, J., Pang, L., & Sack, M. N.
Affiliations
  • Translational Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892-1454
  • National Institutes of Health (US)
Venue
Endocrine Reviews
Published
2009-10-27
Volume
31
Issue
1
Pages
25-51
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W2161339546
Cited by
154
References
333
Citations by year
2026: 6 · 2025: 5 · 2024: 6 · 2023: 6 · 2022: 5 · 2021: 3 · 2020: 13 · 2019: 7 · 2018: 8 · 2017: 8 · 2016: 11 · 2015: 7 · 2014: 15 · 2013: 17 · 2012: 11
FWCI
0.94
Type
journal article
Language
en
Open access
Locations
  • Endocrine Reviews (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institutes of Health
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Physiology › Adipose Tissue and Metabolism
Keywords
skeletal muscle insulin resistance, mitochondrial dysfunction, type 2 diabetes, peripheral insulin resistance, mitochondrial DNA variants, mitochondrial-targeted therapy, insulin sensitivity, skeletal muscle metabolism
MeSH terms
Animals, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Mitochondria, Muscle, Organ Specificity, Prediabetic State, Muscle, Skeletal, Metabolic Syndrome, Mitochondrial Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review